GLTO Share Price | Galecto, Inc. Stock Analysis & Recommendation

Q: Is Galecto, Inc. technically bullish or bearish?

As of 29 July 2025, the technical trend for Galecto, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven primarily by the daily moving averages indicating a bearish trend. While the weekly MACD shows a mildly bullish signal, the overall indicators such as Bollinger Bands and KST are leaning bearish on both weekly and monthly time frames. The RSI is bullish on a monthly basis but shows no signal weekly, indicating mixed momentum. In terms of performance, Galecto has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -38.28% compared to the S&P 500's 12.22%, and a one-year return of -79.1% against 17.14% for the index.

Q: How big is Galecto, Inc.?

Market Cap: As of Jun 18, Galecto, Inc. has a market capitalization of 4.26 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Galecto, Inc. reported net sales of 0.00 million and a net profit of -18.49 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 14.47 million and total assets of 17.13 million.

Q: What does Galecto, Inc. do?

Overview: Galecto, Inc. is a clinical-stage biotechnology company focused on developing therapeutics targeting fibrosis and related diseases within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) Market-cap: USD 4.26 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.86 Return on Equity: -106.34% Price to Book: 0.34Contact Details: Address: Galecto Biotech Ab, Ole Maaloes Vej3, COPENHAGEN DE: DK-2200 Website: https://galecto.com/

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

121.7 k

Shareholding (Mar 2026)

FII

0.47%

Held by 10 FIIs

DII

95.99%

Held by 16 DIIs

Promoter

3.54%

Is Galecto, Inc. technically bullish or bearish?

20-Sep-2025

As of July 29, 2025, Galecto, Inc. is in a mildly bearish trend with daily moving averages indicating bearish momentum, despite mixed signals from weekly MACD and RSI, and has significantly underperformed the S&P 500 with a year-to-date return of -38.28%.

View full answer

How big is Galecto, Inc.?

22-Jun-2025

As of Jun 18, Galecto, Inc. has a market capitalization of 4.26 million, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -18.49 million over the latest four quarters. The company reported shareholder's funds of 14.47 million and total assets of 17.13 million as of Dec 24.

View full answer

What does Galecto, Inc. do?

22-Jun-2025

Galecto, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for fibrosis and related diseases. As of March 2025, it has a market cap of $4.26 million and reported a net profit loss of $3 million.

View full answer

Compare Galecto, Inc. with Similar Stocks

Acurx Pharmaceuticals, Inc.Acorda Therapeutics, Inc.Cosmos Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 1,538 Million (Small Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.07

Return on Equity

-14.86%

Price to Book

6.43

Revenue and Profits:

Net Sales:

(Quarterly Results - Mar 2026)

Net Profit:

-28 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-0.48%

6 Months

-21.11%

1 Year

580.71%

2 Years

84.44%

3 Years

796.09%

4 Years

-47.57%

5 Years

-81.46%

Galecto, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-2.93%

EBIT to Interest (avg)

-37.53

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.86

Sales to Capital Employed (avg)

Tax Ratio

0.18%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

6.75%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

6.43

EV to EBIT

-35.05

EV to EBITDA

-35.08

EV to Capital Employed

-74.38

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-14.86%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Sideways

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bullish

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2026

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 6 Schemes (15.72%)

Foreign Institutions

Held by 10 Foreign Institutions (0.47%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Mar 2026 is -1,012.00% vs 54.55% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-30.80",
          "val2": "-2.60",
          "chgp": "-1,084.62%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.80",
          "val2": "-2.50",
          "chgp": "-1,012.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is -880.37% vs 44.13% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-36.50",
          "val2": "-16.70",
          "chgp": "-118.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-174.30",
          "val2": "-5.40",
          "chgp": "-3,127.78%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-209.80",
          "val2": "-21.40",
          "chgp": "-880.37%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY

Mar'26

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-30.80

-2.60

-1,084.62%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-27.80

-2.50

-1,012.00%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Mar 2026 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

YoY Growth in quarter ended Mar 2026 is -1,012.00% vs 54.55% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-36.50

-16.70

-118.56%

Interest

0.00

Exceptional Items

-174.30

-5.40

-3,127.78%

Consolidate Net Profit

-209.80

-21.40

-880.37%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is -880.37% vs 44.13% in Dec 2024

All Annual Results

Company CV

About Galecto, Inc.

Galecto, Inc.

Pharmaceuticals & Biotechnology

Galecto Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. The Company’s initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2 (LOXL2). The Company is developing GB0139 for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF), a life-threatening progressive fibrotic disease of the lung. The Company’s product candidate portfolio also includes GB1211, a selective oral galectin-three inhibitor, which is being developed for the treatment of fibrosis related to non-alcoholic steatohepatitis (NASH), and GB2064, a selective oral inhibitor of LOXL2 for the treatment of myelofibrosis, a malignant disease of the bone marrow in which fibrosis reduces the ability to form blood cells.

Company Coordinates

Company Details

Galecto Biotech Ab, Ole Maaloes Vej3 , COPENHAGEN DE : DK-2200

Tel:

https://galecto.com/

Registrar Details